U.S. net product revenue for the three and nine months ended September 30, 2024, was $31.1 million and $84.2 million, respectively, compared to $20.3 million and $57.6 million for the comparable ...

Topline data from pivotal Phase 3 TANDEM trial now expected in 4Q 2024 due to faster than expected enrollment – – On-track to report topline data from pivotal Phase 3 BROADWAY trial in 4Q 2024 – – ...

Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their ...

Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ...

ABSTRACT: Objective: To evaluate the bioequivalence (BE) of two fixed-dose combination (FDC) formulations of Rosuvastatin and Ezetimibe: Cresadex® EZE 20/10 mg (Abbott Laboratories) as the reference ...

"We continue to be impressed with and encouraged by the strong adoption and growing product revenue our European partner, Daichi Sankyo Europe (DSE), is generating across Europe bringing the LDL-C ...

4 To reduce risk of: myocardial infarction, coronary revascularization, stroke, or morbidity/mortality; see full labeling for each drug’s specific indication. Not an inclusive list of ...

Am J Health Syst Pharm. 2006;63(23):2340-2348. MDR1 (ABCB1) T-129C, C1236T, G2677(T,A), C3435T No difference observed for cyclosporine and any CYP3A5 polymorphism Wild-type carriers of MDR1 (ABCB1 ...